Parenteral Iron Therapy for Pediatric Patients

被引:1
作者
Mantadakis, Elpis [1 ]
Alexiadou, Sonia [1 ]
Zikidou, Panagiota [1 ]
机构
[1] Univ Gen Hosp Alexandroupolis, Dept Pediat, Hematol Oncol Unit, Alexandroupolis 68100, Greece
来源
HEMATO | 2024年 / 5卷 / 01期
关键词
iron deficiency; iron deficiency anemia; intravenous iron; iron sucrose; ferric carboxymaltose; iron isomaltoside; inflammatory bowel diseases; INFLAMMATORY-BOWEL-DISEASE; MOLECULAR-WEIGHT IRON; DEFICIENCY ANEMIA; FERRIC CARBOXYMALTOSE; CHILDREN; EFFICACY; MANAGEMENT; DEXTRAN; SAFETY; HYPERSENSITIVITY;
D O I
10.3390/hemato5010005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Iron deficiency (ID) is by far the most common nutritional disorder in developing and developed countries. When left untreated, ID leads to anemia. Although the usually recommended treatment for iron deficiency anemia (IDA) is oral iron therapy with countless products, such therapy necessitates administration for >3-6 months with questionable patient compliance since most oral iron products have an unpleasant metallic aftertaste and cause intestinal side effects. In addition, in certain gastrointestinal conditions, such as inflammatory bowel diseases or untreated gluten-sensitive enteropathy, oral iron therapy is contraindicated or unsuccessful. Intravenous iron is considered safe in adults, where adverse events are mild and easily managed. The experience with parenteral iron in children is much more limited, and many pediatricians appear reluctant to use it because of uncorroborated fears of serious anaphylactic reactions. In the current article, we thoroughly review the available pediatric literature on the use of all commercially available parenteral iron products except ferumoxytol, which was recently removed from the market. We conclude that parenteral iron appears to be safe in children; it works faster than oral iron, and the newer third-generation products allow replacement of the total iron deficit in a single sitting.
引用
收藏
页码:35 / 47
页数:13
相关论文
共 50 条
  • [41] The iron revolution: Keeping abreast of the developments in iron therapy COMMENT
    Auerbach, Michael
    Macdougall, Iain C.
    Rodgers, George M.
    Deloughery, Tom
    Richards, Toby
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 250 - 252
  • [42] Safety, therapeutic effectiveness, and cost of parenteral iron therapy
    Asma, Suheyl
    Boga, Can
    Ozdogu, Hakan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (01) : 24 - 27
  • [43] Intravenous Iron Sucrose for Children With Iron Deficiency Failing to Respond to Oral Iron Therapy
    Crary, Shelley E.
    Hall, Katherine
    Buchanan, George R.
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 615 - 619
  • [44] Real-world evaluation of an intravenous iron service for the treatment of iron deficiency in patients with gastroenterological disorders
    Kearns, Jackie
    Jacob, Sudheer George
    FRONTLINE GASTROENTEROLOGY, 2021, 12 (04) : 265 - 271
  • [45] A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy
    Hetzel, David
    Strauss, William
    Bernard, Kristine
    Li, Zhu
    Urboniene, Audrone
    Allen, Lee F.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : 646 - 650
  • [46] Iron therapy: Indications, limitations and modality
    Arlet, J-B
    Pouchot, J.
    Lasocki, S.
    Beaumont, C.
    Hermine, O.
    REVUE DE MEDECINE INTERNE, 2013, 34 (01): : 26 - 31
  • [47] Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder
    Geisser, Peter
    Rumyantsev, Vitaly
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2010, 60 (6A): : 373 - 385
  • [48] Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
    Rostoker, Guy
    Lepeytre, Fanny
    Merzoug, Myriam
    Griuncelli, Mireille
    Loridon, Christelle
    Boulahia, Ghada
    Cohen, Yves
    PHARMACEUTICS, 2022, 14 (07)
  • [49] Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
    Jensen, Gert
    Goransson, Lasse G.
    Femstrom, Anders
    Furuland, Hans
    Christensen, Jeppe H.
    CLINICAL NEPHROLOGY, 2019, 91 (04) : 246 - 253
  • [50] Evaluation of Parenteral Iron Therapy in Ambulatory Older Adults with Iron Deficiency Anaemia
    Casteleyn, Ilse
    Joosten, Etienne
    ACTA HAEMATOLOGICA, 2017, 138 (04) : 221 - 222